TrialClinical and translational science2024

First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.

Hidetoshi Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.